Kalcipos-Vitamin D (Colecalciferol, Calcium)

Colecalciferol is absorbed in the intestine and converted first to 25‑hydroxyvitamin D in the liver, then to the active hormone 1,25‑dihydroxyvitamin D in the kidney. This active form binds to vitamin D receptors, increasing transcription of proteins that enhance calcium and phosphate absorption from the gut, thereby supporting bone health.

The appropriate dose of Kalcipos-Vitamin D is determined by the prescribing healthcare professional based on the patient’s age, laboratory values, and clinical condition. Dosage may vary widely, and the prescriber will tailor the regimen to achieve optimal calcium and vitamin D status.

Kalcipos-Vitamin D may be used during pregnancy and lactation if the prescriber judges it necessary, as vitamin D and calcium are essential nutrients for fetal bone development and maternal health. However, the prescriber should assess individual risk‑benefit and monitor serum levels to avoid excess.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kalcipos-Vitamin D combines both colecalciferol and calcium in a single oral formulation, whereas many vitamin D products contain only the vitamin. This dual composition can simplify therapy for patients who need both nutrients, potentially improving adherence compared with taking separate calcium and vitamin D preparations.

Store Kalcipos-Vitamin D at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Kalcipos-Vitamin D is taken orally, usually with water. The prescriber may advise taking it with food to improve calcium absorption and reduce gastrointestinal discomfort. Patients should follow the dosing schedule provided by their healthcare professional.

The most serious risks involve excessive calcium levels, such as severe hypercalcemia, which can cause cardiac arrhythmias, kidney stones, or renal impairment. Rarely, allergic reactions or hypervitaminosis D may occur. Patients should report symptoms like persistent nausea, vomiting, confusion, or irregular heartbeat to a clinician promptly.

Kalcipos-Vitamin D should be avoided in individuals with known hypersensitivity to colecalciferol or calcium, those with untreated hypercalcemia, severe renal disease, or conditions predisposing to calcium overload. The prescriber must evaluate each patient’s medical history before initiating therapy.